Effect of Initial Ziprasidone Dose on Treatment Outcome of Korean Patients with Acute Manic or Mixed Episodes
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Woo, Young Sup | - |
dc.contributor.author | Bahk, Won-Myong | - |
dc.contributor.author | Jo, Soo Hyun | - |
dc.contributor.author | Yoon, Bo-Hyun | - |
dc.contributor.author | Lee, Jung Goo | - |
dc.contributor.author | Kim, Won | - |
dc.contributor.author | Jeong, Jong-Hyun | - |
dc.contributor.author | Seo, Jeong Seok | - |
dc.contributor.author | Min, Kyung Joon | - |
dc.contributor.author | Jon, Duk-In | - |
dc.date.available | 2019-05-29T11:36:48Z | - |
dc.date.issued | 2011-09 | - |
dc.identifier.issn | 1738-3684 | - |
dc.identifier.issn | 1976-3026 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/21301 | - |
dc.description.abstract | Objective We investigated the efficacy and tolerability of ziprasidone combined with divalproex to determine the relationship between the initial dose of ziprasidone and the treatment effect among Korean patients with acute bipolar manic or mixed disorders. Methods This study was a 6-week, open-label, prospective investigation of Korean patients with an acute manic or mixed episode of bipolar disorder. Sixty-five patients were recruited. The patients were categorized based on the initial dose of ziprasidone as follows: low (2079 mg/day) and standard (80 mg/day). Ziprasidone was given in combination with divalproex in flexible doses, according to the clinical response and tolerability. Results The response and remission rates were significantly higher in the standard-dose group than the low-dose group. The combination of ziprasidone and divalproex was well-tolerated and adverse events were mostly mild with no statistically significant increase in body weight. Conclusion The results of this study showed that a standard starting dose of ziprasidone in combination with divalproex for bipolar disorder is more effective than a low starting dose. Psychiatry Investig 2011;8:207-213 | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN NEUROPSYCHIATRIC ASSOC | - |
dc.title | Effect of Initial Ziprasidone Dose on Treatment Outcome of Korean Patients with Acute Manic or Mixed Episodes | - |
dc.type | Article | - |
dc.identifier.doi | 10.4306/pi.2011.8.3.207 | - |
dc.identifier.bibliographicCitation | PSYCHIATRY INVESTIGATION, v.8, no.3, pp 207 - 213 | - |
dc.identifier.kciid | ART001633199 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000295116300005 | - |
dc.identifier.scopusid | 2-s2.0-80053340245 | - |
dc.citation.endPage | 213 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 207 | - |
dc.citation.title | PSYCHIATRY INVESTIGATION | - |
dc.citation.volume | 8 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | Bipolar disorder | - |
dc.subject.keywordAuthor | Divalproex | - |
dc.subject.keywordAuthor | Initial dose | - |
dc.subject.keywordAuthor | Manic episode | - |
dc.subject.keywordAuthor | Ziprasidone | - |
dc.subject.keywordPlus | ACUTE BIPOLAR MANIA | - |
dc.subject.keywordPlus | INDUCED WEIGHT-GAIN | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | I-DISORDER | - |
dc.subject.keywordPlus | SCHIZOAFFECTIVE DISORDER | - |
dc.subject.keywordPlus | MOOD STABILIZER | - |
dc.subject.keywordPlus | RATING-SCALE | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | SCHIZOPHRENIA | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.